Related references
Note: Only part of the references are listed.Vorinostat Increases Expression of Functional Norepinephrine Transporter in Neuroblastoma In Vitro and In Vivo Model Systems
Swati S. More et al.
CLINICAL CANCER RESEARCH (2011)
Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force
K. K. Matthay et al.
BRITISH JOURNAL OF CANCER (2010)
Comparison of High-Specific-Activity Ultratrace 123/131I-MIBG and Carrier-Added 123/131I-MIBG on Efficacy, Pharmacokinetics, and Tissue Distribution
John A. Barrett et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2010)
Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET
Chang-Lae Lee et al.
MEDICAL PHYSICS (2010)
Optimization and assessment of quantitative 124I imaging on a Philips Gemini dual GS PET/CT system
Rebecca A. Gregory et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Iodine-131-Metaiodobenzylguanidine Double Infusion With Autologous Stem-Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma Therapy Phase I Study
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Comparison of Iodine-123 Metaiodobenzylguanidine (MIBG) Scan and [18F]Fluorodeoxyglucose Positron Emission Tomography to Evaluate Response After Iodine-131 MIBG Therapy for Relapsed Neuroblastoma
Denah R. Taggart et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
123I-MIBG Scintigraphy and 18F-FDG PET in Neuroblastoma
Susan E. Sharp et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Neuroblastoma: Biology and Staging
Sabine Mueller et al.
CURRENT ONCOLOGY REPORTS (2009)
Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma
Steven G. DuBois et al.
NUCLEAR MEDICINE AND BIOLOGY (2008)
In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neurobtastoma
Paxton V. Dickson et al.
JOURNAL OF PEDIATRIC SURGERY (2007)
Imaging hNET reporter gene expression with 124I-MIBG
Maxim A. Moroz et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Dosimetry for fractionated 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma:: Preliminary results
Susan E. Buckley et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2007)
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study
KK Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
[131I]meta-ldobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter
AG McCluskey et al.
CLINICAL CANCER RESEARCH (2005)
Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma
MN Gaze et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2005)
Monte Carlo modeling of gamma cameras for I-131 imaging in targeted radiotherapy
D Autret et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2005)
Share Paper
